|
|
|
|
|
|
|
|
Abstract
Purpose
The aim of the
present study was to investigate, in ovarian carcinoma cases, the
predictive association between the treatment-free interval (TFI) after
an initial paclitaxel plus carboplatin (TC) therapy and the subsequent
effectiveness of a second-line taxane-containing chemotherapy.
Methods
Patients with a
TFI < 6 months from the first-line TC therapy were treated with a
combination chemotherapy using docetaxel and irinotecan; patients with a
TFI ≥ 6 months were retreated with the same regimen as the initial TC
therapy. The clinical data of these patients were retrospectively
analyzed for this study.
Results
The response rate of those with a TFI equal to 6–12 months was greater than that of those with a TFI < 6 months (p = 0.014) and less than that of those with a TFI > 12 months (p = 0.012).
The progression-free survival of the cases with TFI equal to
6–12 months was longer than that of those with TFI < 6 months (p = 0.012) and shorter than that of those with TFI > 12 months (p = 0.0011). Overall survival of cases with a TFI equal to 6–12 months was longer than that of those with TFI < 6 months (p = 0.012) and shorter than that of those with TFI > 12 months (p = 0.0005).
Conclusions
The effectiveness of
using a second-line taxane-containing chemotherapy was shown to be
predictable by the TFI after the first-line taxane-containing
chemotherapy, implying that the theory of ‘taxane-sensitivity’ may be
applied for second-line chemotherapy in the same way as that of
‘platinum-sensitivity’.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.